Evidence map›Paper›PMID 27106024›Full record

ArticleCancer immunology, immunotherapy : CII2016

Immunobiology and immunosurveillance in patients with intraductal papillary mucinous neoplasms (IPMNs), premalignant precursors of pancreatic adenocarcinomas.

Pamela L Beatty, Rick van der Geest, Jana G Hashash, Takashi Kimura, Dmitriy Gutkin, Randall E Brand, Olivera J Finn

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer immunology, immunotherapy : CII, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed, 2 pooled it
2.4field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 2 syntheses or guidelines pooled it, 54 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Abnormal MUC1 Expression as a Biomarker for Pouchitis.Digestive diseases and sciences · 2026
    Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Pamela L BeattyDepartment of Immunology, University of Pittsburgh School of Medicine, 200 Lothrop Street, E1040 BST, Pittsburgh, PA, 15261, USA.
Rick van der GeestDepartment of Immunology, University of Pittsburgh School of Medicine, 200 Lothrop Street, E1040 BST, Pittsburgh, PA, 15261, USA.
Jana G HashashDepartment of Internal Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
Takashi KimuraDepartment of Regenerative Surgery, Fukushima Medical University, Fukushima, Japan.
Dmitriy GutkinDepartment of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Randall E BrandDepartment of Internal Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
Olivera J FinnDepartment of Immunology, University of Pittsburgh School of Medicine, 200 Lothrop Street, E1040 BST, Pittsburgh, PA, 15261, USA. ojfinn@pitt.edu.
University of Pittsburgh · USUniversity of Pittsburgh Medical Center · USFukushima Medical University · JP

Funding

University of Pittsburgh Clinical and Translational Science InstituteUL1TR000005 · NCATS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI REIS, STEVEN E · 2012 to 2015
$50.8M
Dendritic Cell Biology and TherapyR01CA168392 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI FINN, OLIVERA J · 2011 to 2015
$2.0M
NCATS NIH HHS UL1 TR000005NCI NIH HHS R01 CA168392
6 · The paper itself

Abstract

Premalignant lesions for many cancers have been identified, and efforts are currently directed toward identification of antigens expressed on these lesions that would provide suitable targets for vaccines for cancer prevention. Intraductal papillary mucinous neoplasms (IPMNs) are premalignant pancreatic cysts of which a subset has the potential to progress to cancer. Currently, there are no validated predictive markers for progression to malignancy. We hypothesized that the presence or absence of immune surveillance of these lesions would be one such factor. Here we show that the tumor antigen MUC1, which is abnormally expressed on pancreatic cancer and is a target for cancer immunosurveillance, is also abnormally expressed on premalignant IPMN. We show that some IPMN patients make MUC1-specific IgG. Moreover, we show evidence of CD4 and CD8 T cell infiltration into IPMN areas of high dysplasia suggesting an ongoing immune response within the lesions. We also found, however, increased levels of circulating myeloid-derived suppressor cells (MDSCs) and regulatory T cells (Tregs) in some IPMN patients as well as evidence of T cell exhaustion. Further studies correlating immunosurveillance or immunosuppression with IPMN progression to malignancy will help define the immune response as a biomarker of risk, leading potentially to a vaccine to boost spontaneous immunity and prevent progression to cancer.

Indexed as

AdenocarcinomaAdenocarcinoma, MucinousBiomarkers, TumorCarcinoma, Pancreatic DuctalFemaleHumansImmunohistochemistryMaleMonitoring, ImmunologicMucin-1Pancreatic NeoplasmsPrecancerous ConditionsBiomarkers, TumorMUC1 protein, humanMucin-1Cancer vaccinesCITIM 2015ImmunosurveillanceIPMNMUC1Pancreatic cancer

Identifiers

PMID27106024
PMCPMC11028509
OpenAlexW2341543647

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.